Table 1.
Demographics and Characteristics of the Study Population
| Demographic Characteristics | Childrena (n = 90) | Adults (n = 232) |
|---|---|---|
| Age, y, mean (SD) | 9.1 (3.9) | 45.6 (12.9) |
| Female, n (%) | 50 (55.6) | 177 (76.3) |
| Age at symptom onset, y, mean (SD) | 1.3 (1.9) | 3.2 (7.2) |
| Age at diagnosis of XLH, y, mean (SD) | 2 (2.2) | 9.3 (13.5) |
| Self-reported PHEX mutation, n (%) | 53 (58.9) | 90 (39.0) |
| Current use of oral phosphate and active vitamin D, n (%) | 89 (98.9) | 110 (47.4) |
| Current use of oral phosphate, n (%) | 89 (98.9) | 114 (49.1) |
| Current use of active vitamin D, n (%) | 89 (98.9) | 149 (64.2) |
| Previous participation in a clinical trial with burosumab, n (%) | 3 (3.3) | 23 (9.9) |
| Current use of burosumab, n (%) | 1 (0.1) | 0 (0.0) |
a
Note that a caregiver filled out the pediatric survey for an 18.9-y-old individual with XLH and the responses are included in the pediatric dataset.